Previous 10 | Next 10 |
Adverum Biotechnologies (NASDAQ: ADVM ) initiated with Buy rating and $17 (36% upside) price target at Goldman Sachs. More news on: Adverum Biotechnologies, Inc., Alector, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Source : ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Read more ...
Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...
SHANGHAI, China, and SAN FRANCISCO, April 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that the Center for Drug Evaluation of China’s National Medical Products Administration...
Deals and Financings Qiming closed its seventh China-focused US dollar fund with $1.1 billion for early stage Healthcare and TMT investments. Currently, Qiming manages nine US dollar funds and five RMB funds with $5.3 billion of assets under management. Despite the COVID-19 pandemic, Qimin...
The most important thing is to survive the outbreak. Thereafter, for our portfolio to survive too so it can do well when the situation is favorable. Market Pulse The stock market remains unsettled and vulnerable to sharp declines. Over the last two weeks, the market has forcefully steppe...
Regeneron Pharmaceuticals (NASDAQ: REGN ) will collaborate with Zai Lab Limited (NASDAQ: ZLAB ) to develop and commercialize REGN1979, a CD20xCD3 bispecific antibody, in Greater China (mainland China, Hong Kong, Taiwan and Macau). The partnership will start with a pivotal Phase 2 study in ...
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau Collaboration will also support enrollment of regional patients into Regeneron’s global trials evaluating REGN1979 in B-cell non-Hodgkin lymphoma ...
Market Pulse This week all the major indexes made new lows. The market continues to be under stress and this is not the final low. Biotechs were one of the few industry groups that didn't make a new low this week. A respite from non-stop selling will come from the economic stimulus package w...
Deals and Financings InnoCare Pharma of Beijing priced its Hong Kong IPO at the top end of its proposed range to raise $288 million at a $1 billion valuation, according to insiders. The company develops immunotherapies for cancer and autoimmune diseases. It has three molecules in clinical ...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...